Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Lenvatinib Mesylate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Eisai's Kisplyx (lenvatinib mesilate) Receives Approval for Europe
    Eisai's Kisplyx (lenvatinib mesilate) Receives Approval for Europe

    26 Oct 2018

    // EMA

    https://www.ema.europa.eu/documents/product-information/kisplyx-epar-product-information_en.pdf

    EMA
    26 Oct 2018
    Share Share
    Eisai, MSD start marketing activity for LENVIMA
    Eisai, MSD start marketing activity for LENVIMA

    25 Oct 2018

    // BIOSPECTRUM

    https://www.biospectrumasia.com/news/25/11929/eisai-msd-start-marketing-activity-for-lenvima.html

    BIOSPECTRUM
    25 Oct 2018
    Share Share
    Eisai Co., Ltd. and Merck Enter Global Strategic Oncology Collaboration for LENVIMA® (lenvatinib mesylate)
    Eisai Co., Ltd. and Merck Enter Global Strategic Oncology Collaboration for LENVIMA® (lenvatinib mesylate)

    07 Mar 2018

    // NASDAQ

    https://www.nasdaq.com/press-release/eisai-co-ltd-and-merck-enter-global-strategic-oncology-collaboration-for-lenvima-lenvatinib-mesylate-20180307-01372

    NASDAQ
    07 Mar 2018
    Share Share
    Eisai & Merck Receive Breakthrough Therapy Designation from FDA for LENVIMA
    Eisai & Merck Receive Breakthrough Therapy Designation from FDA for LENVIMA

    09 Jan 2018

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/eisai-and-merck-receive-breakthrough-therapy-designation-from-fda-for-lenvima-lenvatinib-mesylate-and-keytruda-pembrolizumab-as-combination-therapy-for-advanced-andor-metastatic-renal-cell-carcinoma-300579517.html

    PR NEWSWIRE
    09 Jan 2018
    Share Share
    PhIII of Anticancer Agent Lenvima Meets Primary Endpoint
    PhIII of Anticancer Agent Lenvima Meets Primary Endpoint

    27 Jan 2017

    // PRESS RELEASE

    http://www.eisai.com/news/news201706.html

    PRESS RELEASE
    27 Jan 2017
    Share Share
    Eisai's Gets EU Nod For Cancer Medicine Kisplyx
    Eisai's Gets EU Nod For Cancer Medicine Kisplyx

    16 Nov 2016

    // EMA

    https://www.pharmacompass.com/pdf/news/eisais-gets-eu-nod-for-cancer-medicine-kisplyx-1479554942.pdf

    EMA
    16 Nov 2016
    Share Share